2012 BIO International Convention Super Sessions Focus on Industry Outlook
WASHINGTON, DC – (March 7, 2012) - The 2012 BIO International Convention will feature six Super Sessions highlighting the state of the industry and the future outlook. Attendees can expect to hear from a dynamic group of C-level speakers from major biotechnology and pharmaceutical companies. Hosted by the Biotechnology Industry Organization (BIO), this year’s global event for biotechnology will take place June 18-21, 2012 at the Boston Convention and Exhibition Center in Boston, MA.
“The Super Sessions will feature key industry executives sharing perspectives on the current economic environment and major trends that will impact the future of the global industry,” said BIO CEO and President Jim Greenwood. “Attendees have come to expect thought-provoking discussions which will offer insight and valuable advice that can be taken home and applied to their own organizational challenges, as well as guidance on possible opportunities for further growth and development.”
Super Sessions include:
Beyond Borders: Ernst & Young’s Annual Biotechnology Industry Report
Ernst & Young will host a session that explores industry trends and themes, including: changing incentives; the ever- increasing volume of industry data; patient-centric R&D and exploring new ways to increase efficiency and improve results in resource-constrained times. The presentation will also summarize the sector’s performance using key metrics — financial performance, financing, deals and pipeline productivity.
Sponsored by Ernst & Young
Tuesday, June 19, 10:00 a.m. – 11:30 a.m.
Moderators: Glen Giovannetti, Partner and Global Biotechnology Leader, Ernst & Young LLP and Gautam Jaggi, Senior Manager and Editor, Beyond Borders and Progressions, Ernst & Young LLP
Burrill State-of-the-Industry Report
This presentation will discuss themes from the new annual report, Biotech 2012: Innovating in the New Austerity. Learn what innovation looks like in 2012, the role it will play in addressing global problems, and how companies will fund it going forward.
Sponsored by Burrill & Company
Tuesday, June 19, 2:00 p.m. – 3:30 p.m.
Speaker: G. Steven Burrill, Chief Executive Officer, Burrill & Company
International Leaders Share Their Worldview: Scientific American’s Regional Bio-Innovation Scorecard
Scientific American's 2012 Worldview will examine the BRICs of the future, emerging markets 2.0 and the future of innovation and key drivers for growth of the global biotechnology industry. The session will include global biotechnology leaders sharing their perspectives on how countries and regions can invest, invent and innovate to dominate the future of the sector.
Tuesday, June 19, 3:45 p.m. – 5:15 p.m.
Moderator & Speaker: Fareed Zakaria, CNN host, Editor-at-Large of TIME Magazine, Washington Post columnist and New York Times bestselling author
After the Honeymoon – Integrating the R&D Growth Engine
Acquisitions are driven largely by lead assets with promise, yet often come with a deep earlier stage R&D engine. Attendees will hear from industry leaders that have made sustained integration a reality. In advance of this interactive panel discussion, Campbell Alliance and BIO will present updated findings from two unique forward-looking measures of deal-making in the industry – the Campbell Alliance Dealmakers’ Intentions Survey and the BIO One-on-One Partnering Forecast.
Sponsored by Campbell Alliance
Wednesday, June 20, 10:00 a.m. – 11:30 a.m.
Moderated by Ben Bonifant, Practice Area Leader, Campbell Alliance and David Thomas, Director, Industry Research & Analysis, Biotechnology Industry Organization
Speaker: Peter Greenleaf, President, MedImmune
Pre-Competitive Collaboration: Innovation of the Future?
Precompetitive collaboration is a growing driver for innovation and increased productivity in biotechnology. This Super Session will explore the benefits and challenges of pre-competitive collaborations to advance research and development of novel medicines. This session will also cover how best to foster a seamless interplay between the elements of the R&D continuum.
Sponsored by Eli Lilly and Company
Wednesday, June 20, 2:00 p.m. – 3:30 p.m.
Speaker: Jan M. Lundberg, PhD, Executive Vice President, Science & Technology and President, Lilly Research Laboratories, Eli Lilly and Company
PDUFA V: Impact on Innovation, Patients, and Modern Medicines
Industry leaders will discuss the reauthorization of the Prescription Drug User Fee Act (PDUFA V) and efforts to modernize the FDA regulatory environment, as well as the implications for patients, providers, and the industry.
Sponsored by MedImmune
Wednesday, June 20, 3:45 p.m. – 5:15 p.m.
Speaker: Peter Greenleaf, President, MedImmune
The BIO International Convention will highlight the latest trends and the newest opportunities for executives, investors, scientists, policy leaders, and media from around the world. Speakers at the sessions will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture. Visit convention.bio.orgfor the most up-to-date program and speaker information.
The Convention also features the BIO Business Forum, a unique platform for biotechnology and pharmaceutical companies, academic research institutions, and investors from around the world to gather and discuss strategic opportunities. For registration, conference agenda and exhibitor information, visit2012 BIO International Convention.
April 29-May 2, 2012
June 18-21, 2012